Under the agreement, Sciele acquired Twinject and certain other related Verus products under development for $29 million. Verus may also receive additional payments resulting from the achievement of certain development milestones.
Twinject is available in 0.3 and 0.15 milligram dosage strengths and is indicated in the emergency treatment of severe allergic reaction including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as anaphylaxis to unknown substance or exercise-induced anaphylaxis. Twinject is said to be the only available product approved by the FDA that contains two doses of epinephrine in a single, compact device.
Patrick Fourteau, CEO of Sciele Pharma, said: “The agreement with Verus allows us to further diversify our product portfolio by adding another new launch to our growing pediatric line.”